See original here:
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
Related Post
- TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk... - May 6th, 2024
- Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 4th, 2024
- Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List - May 4th, 2024
- Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 - May 4th, 2024
- 10 Barrel Brewing Introduces Pub Cerveza: a New Twist on ‘Cheap Fun.’ Series - May 4th, 2024
- MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call - May 4th, 2024
- PDS Biotechnology Announces Details of Virtual KOL Event - May 4th, 2024
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results - May 4th, 2024
- Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 - May 4th, 2024
- Ocuphire Pharma to Present at the Aegis Virtual Conference - May 4th, 2024
- Adverum Biotechnologies to Participate in Upcoming May Investor Conferences - May 4th, 2024
- Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process - May 4th, 2024
- PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy - May 4th, 2024
- Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised... - May 4th, 2024
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024 - May 4th, 2024
- TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer - May 4th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 4th, 2024
- Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million - May 4th, 2024
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting - May 4th, 2024
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - May 4th, 2024
- Compass Pathways to announce first quarter financial results on May 8, 2024 - May 4th, 2024
- Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer - May 2nd, 2024
- Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab - May 2nd, 2024
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems - May 2nd, 2024
- Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference - May 2nd, 2024
- Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 - May 2nd, 2024
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024 - May 2nd, 2024
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting - May 2nd, 2024
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences - May 2nd, 2024
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 - May 2nd, 2024
- SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results - May 2nd, 2024
- Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 - May 2nd, 2024
- Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations - May 2nd, 2024
- CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant - May 2nd, 2024
- Ipsen appoints Keira Driansky as EVP, President of North America - May 2nd, 2024
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 - May 2nd, 2024
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 - May 2nd, 2024
- Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024 - May 2nd, 2024
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein - May 2nd, 2024
- Iktos announces the appointment of Roman Fleck as Chairman of the Board - May 2nd, 2024
- Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing - May 2nd, 2024
- TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented... - April 30th, 2024
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma - April 30th, 2024
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease - April 30th, 2024
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 - April 30th, 2024
- Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve - April 30th, 2024
- Oculis Publishes Invitation to the Annual General Meeting - April 30th, 2024
- OpGen Provides Update on Business Operations and Strategic Opportunities - April 30th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 - April 30th, 2024
- QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance - April 30th, 2024
- ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 - April 30th, 2024
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers... - April 30th, 2024
- Travere Therapeutics to Report First Quarter 2024 Financial Results - April 30th, 2024
- Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - April 30th, 2024
- Better Choice Company Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - April 30th, 2024
- BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results - April 30th, 2024
- Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 - April 30th, 2024
- BeyondSpring Files 2023 Annual Report on Form 20-F - April 30th, 2024
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - April 30th, 2024
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet... - April 30th, 2024
- Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 - April 30th, 2024
- Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
- Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
- Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
- Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
- Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
- Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of... - April 28th, 2024
- Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
- CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
- BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
- Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
- Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
- Financière de Tubize - Dividend approval - April 28th, 2024
Recent Comments